OTC Markets OTCPK · Stocky rates: Cautious

Medicover AB (MCVEY)

$16.55 ▲ +0.00% as of 24 Aug, 13:33

Stocky turns companies like Medicover AB into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.

Try Stocky free →
49
/ 100
Neutral

What Stocky thinks

Cautious. MCVEY's 51/100 composite score reflects modest growth (51 Growth Compounder) offset by weak value metrics (35 Value Compounder) and leadership alignment concerns (52/100). At 27.2× forward P/E, the stock prices in optimism that current fundamentals do not yet justify; financial resilience remains adequate but not exceptional.

Compounder Score
47/100
Business quality — profitability, growth, capital efficiency.
Leadership Alignment
52/100
Founder-led, insider ownership, capital allocation history.
Vulnerability
50/100
Downside resilience — customer concentration, supply chain, refinancing risk.
Value Score
35/100
Valuation vs peers and history — is this a good price to pay?

What Stocky gives investors that other tools don't

Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Medicover AB:

49
VERDICT

Stocky Verdict — one score, everything

Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 49/100, you know instantly whether to dig deeper or skip.

Rated
MOAT

Moat Score — is there a real edge?

Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.

52
LEADER

Leadership Alignment — is management on your side?

Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.

50
RISK

Vulnerability Profile — what could break?

Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.

Elite
TRACK

Track Record — does the system work?

Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.

24/7
ALERTS

Alerts + Portfolio insights

Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.

Medicover AB (MCVEY) — frequently asked

Is Medicover AB (MCVEY) a good investment right now?

Stocky rates Medicover AB (MCVEY) at 49/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. MCVEY's 51/100 composite score reflects modest growth (51 Growth Compounder) offset by weak value metrics (35 Value Compounder) and leadership alignment concerns (52/100). At 27.2× forward P/E, the stock prices in optimism tha

What is MCVEY's Stocky Verdict?

MCVEY's current Stocky Verdict is 49/100, placing it in the "Cautious" band. This composite combines a 47/100 Compounder score, 52/100 Leadership, Moat rating, and analyst signal.

Does Medicover AB have a competitive moat?

Stocky hasn't finalised a Moat Score for Medicover AB yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.

Is Medicover AB's leadership aligned with shareholders?

Medicover AB scores 52/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.

What are the biggest risks to MCVEY?

Medicover AB's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Medicover AB.

This is just the surface. See the whole picture on Medicover AB.

Sign up free and unlock the full analysis on MCVEY — the same tools professional analysts use, personalised to your portfolio:

  • Every analyst covering MCVEY — full list with star ratings, price targets, historical hit-rate. Not just the top 3 you see above.
  • Full Vulnerability Profile — customer concentration, refinancing walls, stress-test scenarios (-20% revenue, +200bp rates) modelled specifically for MCVEY.
  • Bull & bear thesis — the AI-written counter-argument every retail investor forgets to read.
  • Portfolio fit check — how MCVEY changes your sector concentration, correlation and Verdict-weighted quality.
  • Ask Stocky AI — "What are the biggest 3-year risks to MCVEY?" · "Is MCVEY overvalued vs its 5-year median?" · unlimited follow-ups on your portfolio.
  • Live alerts — analyst target changes, insider buys, big moves — the day they happen.
Start free · 14 days Plus, no card →

Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.

STOCKY VERDICT
49
/ 100 · Neutral

See Medicover AB the Stocky way

This page is just a preview. Open the live, interactive version for the full picture:

Stocky Verdict
A plain-English Buy / Hold / Sell score out of 100.
Compounder & Value scores
How strong the business is — and whether it looks cheap.
Interactive charts
1M to 5Y price history with company events plotted on it.
Top analyst targets
What the best-rated Wall Street analysts expect next.
What if? simulator
See what an investment in MCVEY would be worth today.
Practice portfolio
Buy MCVEY with virtual money and track it — zero risk.
Free · no real money · learn by doing Open MCVEY in Stocky →

Or jump straight to the interactive dashboard for MCVEY in the app.